PF-08634404 + Chemotherapy + Nivolumab

Phase 2/3Recruiting

0 views this week 0 watching⚡ Active

Interest: 45/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma

Conditions

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma

Trial Timeline

Mar 2, 2026 → Jul 21, 2032

NCT ID

NCT07392892

About PF-08634404 + Chemotherapy + Nivolumab

PF-08634404 + Chemotherapy + Nivolumab is a phase 2/3 stage product being developed by Pfizer for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07392892. Target conditions include Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer.

What happened to similar drugs?

1 of 4 similar drugs in Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma were approved

Approved (1) Terminated (1) Active (2)

✅Nivolumab + RelatlimabBristol Myers SquibbApproved

🔄Acalabrutinib + Rituximab + ChlorambucilAstraZenecaPhase 3

🔄Surovatamig + R-CHOP + R-CVP + BRAstraZenecaPhase 3

❌Lenalidomide + Dexamethasone + ElotuzumabBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07392892	Phase 2/3	Recruiting	Mar 2, 2026	Jul 21, 2032	Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma

Competing Products

15 competing products in Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma

See all competitors

Product	Company	Stage	Hype Score
Veliparib + Placebo + Modified FOLFIRI + FOLFIRI + Bevacizumab + Fluorouracil infusion	AbbVie	Phase 2	35
Onureg + Venetoclax	AbbVie	Phase 1/2	36
Acalabrutinib + Rituximab + Chlorambucil	AstraZeneca	Phase 3	44
AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin	AstraZeneca	Phase 2	27
Surovatamig + R-CHOP + R-CVP + BR	AstraZeneca	Phase 3	47
MK-3475 + Lenvatinib + Carboplatin + Paclitaxel	Merck	Phase 2	42
UFOX + Cetuximab + FOLFOX4 + Cetuximab	Merck	Phase 2	35
Rituximab + Prednisone + Doxorubicine + Cyclophosphamide + Vincristine	Roche	Phase 2	35
Rituximab + ACVBP regimen plus Pegfilgrastim	Amgen	Phase 2	35
Idelalisib + Nab-paclitaxel + mFOLFOX6	Gilead Sciences	Phase 1	21
Nivolumab + Relatlimab	Bristol Myers Squibb	Approved	50
Lenalidomide + Dexamethasone + Elotuzumab	Bristol Myers Squibb	Phase 3	32
Nivolumab + Albumin-bound paclitaxel + Paricalcitol + Cisplatin + Gemcitabine	Bristol Myers Squibb	Phase 2	35
Pumitamig + Folfox + Capox + Nivolumab	Bristol Myers Squibb	Phase 2/3	45
Pumitamig + FOLFOX + FOLFIRI + Bevacizumab + CAPOX	Bristol Myers Squibb	Phase 2/3	45